Novogene Europe Launches Clinical Sequencing Services for its European Customers
08.03.2021 | 08:01
Quelle: OTS Wirtschaft
Cambridge, England (ots/PRNewswire) - Novogene Europe, a leading provider of genomic services and solutions, has announced the launch of a Clinical Service to provide its European customers with next-generation sequencing (NGS) services and solutions for their clinical samples.
The Clinical Service has launched after Novogene s Cambridge Sequencing Centre was awarded IS0/IEC 17025 accreditation, the highest recognised quality standard in the world for calibrating and testing laboratories. Accreditation means the lab consistently produces precise and accurate test data and has implemented a rigorous quality management system.
The Cambridge Sequencing Centre ISO/IEC 17025 accreditation follows on from CLIA accreditation for the California Clinical Laboratory in the USA, and CAP accreditation, received in 2017, for the Tianjin Medical Lab in China.
Novogene Europe Launches Clinical Sequencing Services for its European Customers
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Novogene Europe Launches Clinical Sequencing Services for its European Customers
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
In order to protect California jobs and preserve the state’s ability to provide critical services to Medi-Cal patients, Assemblywoman Cottie Petrie-Norris is reintroducing legislation to remove the 80% of Medicare cap on reimbursement rates for laboratories in California.
Congressional action in 2018 upended the intent of California’s 2012 Budget Act which maintained a market-based method to determine the fee-for-service Medi-Cal reimbursement rate for lab services. The result was an automatic cut to our carefully calculated Medi-Cal lab rates. Without a change in policy, California will continue to undermine providers’ and laboratories’ ability to confront the COVID-19 pandemic and other health crises such as the ongoing STI epidemic. With the removal of the cap, California labs would be able to avoid this federally triggered cut and operate how the state originally intended.